Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.

Trial Details

NCT ID
NCT06959511
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Thyroid Cancer
Interventions
  • Zanzalintinib
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Houston, Texas, United States|29.76328,-95.36327
  • Charlottesville, Virginia, United States|38.02931,-78.47668

Key Eligibility Criteria

  • Eligibility Criteria
  • Participants with differentiated thyroid cancer, non-RET-mutated medullary thyroid cancer, or poorly differentiated thyroid cancer who present with…
  • At least 18 years of age on the day of signing informed consent.
  • Pathologic findings supporting the clinical impression of papillary thyroid cancer, follicular thyroid cancer, oncocytic thyroid cancer, medullary …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →